Literature DB >> 16505747

The value of contraception to prevent perinatal HIV transmission.

Heidi W Reynolds1, Barbara Janowitz, Rick Homan, Laura Johnson.   

Abstract

OBJECTIVE: The objective of this study was to highlight the value of preventing unintended pregnancies among HIV-infected women as a strategy to prevent perinatal HIV transmission. GOAL: The goal of this study was to assess the cost-effectiveness of family planning programs to avert HIV-positive births with the current programmatic emphasis: prenatal care services that provide and promote nevirapine for prevention of mother-to-child transmission of HIV. STUDY
DESIGN: Cost-effectiveness analyses were conducted from the health system perspective during 1 year with a hypothetical sub-Saharan African population. Expected program costs were combined with number of HIV-positive births averted for each strategy.
RESULTS: At the same level of expenditure, the contraceptive strategy averts 28.6% more HIV-positive births than nevirapine for prevention of mother-to-child transmission of HIV.
CONCLUSIONS: Increasing contraceptive use among nonusers of contraception who do not want to get pregnant is cost-effective and is an equally important strategy to prevent perinatal transmission as prenatal care programs that provide and promote nevirapine to HIV-infected mothers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505747     DOI: 10.1097/01.olq.0000194602.01058.e1

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  65 in total

1.  Population growth and the MDGs.

Authors:  Malcolm Potts
Journal:  J R Soc Med       Date:  2007-06       Impact factor: 5.344

2.  Integrating family planning services into HIV care and treatment clinics in Tanzania: evaluation of a facilitated referral model.

Authors:  Joy Noel Baumgartner; Mackenzie Green; Mark A Weaver; Gottlieb Mpangile; Thecla W Kohi; Stella N Mujaya; Christine Lasway
Journal:  Health Policy Plan       Date:  2013-07-26       Impact factor: 3.344

3.  Assessing the importance of gender roles in couples' home-based sexual health services in Malawi.

Authors:  Jessica D Gipson; Carie J Muntifering; Felluna K Chauwa; Frank Taulo; Amy O Tsui; Michelle J Hindin
Journal:  Afr J Reprod Health       Date:  2010-12

Review 4.  The spread, treatment, and prevention of HIV-1: evolution of a global pandemic.

Authors:  Myron S Cohen; Nick Hellmann; Jay A Levy; Kevin DeCock; Joep Lange
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

5.  Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe.

Authors:  Charles S Morrison; Pai-Lien Chen; Immaculate Nankya; Anne Rinaldi; Barbara Van Der Pol; Yun-Rong Ma; Tsungai Chipato; Roy Mugerwa; Megan Dunbar; Eric Arts; Robert A Salata
Journal:  J Acquir Immune Defic Syndr       Date:  2011-06-01       Impact factor: 3.731

Review 6.  Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.

Authors:  Andrea R Thurman; Sharon Anderson; Gustavo F Doncel
Journal:  Am J Reprod Immunol       Date:  2014-02-13       Impact factor: 3.886

7.  Making family planning accessible in resource-poor settings.

Authors:  Ndola Prata
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-10-27       Impact factor: 6.237

8.  Family planning and HIV: strange bedfellows no longer.

Authors:  Rose Wilcher; Willard Cates; Simon Gregson
Journal:  AIDS       Date:  2009-11       Impact factor: 4.177

9.  Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative.

Authors:  Elizabeth M Stringer; Mark Giganti; Rosalind J Carter; Wafaa El-Sadr; Elaine J Abrams; Jeffrey Sa Stringer
Journal:  AIDS       Date:  2009-11       Impact factor: 4.177

Review 10.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.